Corixa, Massachusetts Institute of Technology deal

CRXA acquired an exclusive worldwide license to the therapeutic rights to the Wilm's tumor gene ( WT1) from MIT. Over-expression of the gene occurs in a large percentage of patients with leukemia, CRX...